NCT04153981View on ClinicalTrials.gov

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

PHASE4CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

July 30, 2021

Study Completion Date

July 30, 2021

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Insulin Glargine

Administered SC

Trial Locations (11)

110026

Maharaja Agrasen Hospital, New Delhi

110060

Sir Ganga Ram Hospital, New Delhi

208002

GSVM Medical College, Kanpur

221004

Popular Hospital, Varanasi

380006

Gujarat Endocrine Center, Ahmedabad

380015

DIACARE, Ahemdabad

390001

Government Medical College & Sir Sayajirao General Hospital, Vadodara

391760

Sumandeep Vidhyapeeth & Dhiraj General Hospital, Vadodara

395002

Nirmal Hospital Private Limited, Surat

422002

Supe Heart & Diabetes Hospital & Research Centre, Nashik

560043

Bangalore Diabetes Center, Bangalore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04153981 - A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India | Biotech Hunter | Biotech Hunter